. Author manuscript; available in PMC: 2016 Aug 1.

Published in final edited form as: Am J Kidney Dis. 2015 Mar 17;66(2):266–273. doi: 10.1053/j.ajkd.2015.01.021

Table 2.

Association of plasma CX3CL1 (fractalkine) with self-reported CVD at baseline

	OR (95% CI)^†	P value
Model 1	1.29 (1.20–1.38)	<0.001
Model 2	1.21 (1.13–1.31)	<0.001
Model 3	1.17 (1.08–1.26)	<0.001
Model 4	1.09 (1.01–1.19)	0.03
Model 5	1.09 (1.01–1.19)	0.03

Note: Prevalent CVD is defined as prior myocardial infarction or coronary revascularization at baseline (n with any CVD=1227). Model 1: CX3CL1 + Demographic factors (age, sex, race); Model 2: CX3CL1 + Demographic factors + Traditional risk factors (diabetes, hypertension, hyperlipidemia, tobacco use, body mass index); Model 3: CX3CL1 + Demographic factors + Traditional risk factors + plasma inflammatory biomarkers (log transformed IL6, tumor necrosis factor α and high-sensitivity C-reactive protein); Model 4: CX3CL1 + Demographic factors + Traditional risk factors + plasma inflammatory biomarkers + kidney function measures (estimated glomerular filtration rate using equation from Chronic Renal Insufficiency Cohort Study data¹⁶ and log transformed urinary albumin-creatinine ratio); Model 5: CX3CL1 + Demographic factors + Traditional risk factors + plasma inflammatory biomarkers + kidney function measures + metabolic syndrome

CI, confidence interval; CVD, cardiovascular disease; OR, odds ratio

^†

for one standard deviation increase in standardized CX3CL1